Quantcast

Latest Ridaforolimus Stories

2014-04-16 00:21:06

TOKYO, April 16, 2014 /PRNewswire/ -- Ajinomoto Pharmaceuticals Co., Ltd. announced on April 16 that the abstract of phase 2a clinical study data of an oral alpha 4 integrin antagonist, development code AJM300, has been accepted for presentation at the Digestive Disease Week 2014 (May 3 - 6 in Chicago, USA). The contents of data will be presented at the beginning of Joint Presidential Plenary Session collaborated by the American Society for Gastrointestinal Endoscopy and the American...

2014-01-09 16:25:42

Highlights Include ICT-107 Results to Date, Ongoing Data Analyses and Phase III Planning LOS ANGELES, Jan. 9, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today issued the following letter to shareholders providing an update on the Company's ICT-107 clinical program in patients with newly diagnosed glioblastoma (GBM). (Logo: http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO) To Our Shareholders: Since the December 11, 2013 announcement of...

2011-04-20 06:30:00

MOUNTAIN VIEW, Calif., April 20, 2011 /PRNewswire/ -- Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the release of the iDimerize inducible dimerization systems. Based on the widely used ARGENT(TM) technology developed by ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA), the iDimerize systems enable precise, real-time control of protein-protein interactions using specific cell-permeable chemical ligands, called dimerizers. Any cellular process that can...

2008-11-06 09:00:45

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the third quarter and nine months ended September 30, 2008 and provided an update on corporate developments. Revised Financial Guidance The Company updated its financial guidance for the year ending December 31, 2008, estimating a net loss of $73 million to $75 million, a decrease as compared to its previous guidance of $81 million to $84 million, and cash used in operations of $39 million to $40...

2008-10-24 09:00:07

Ariad Pharmaceuticals has reported encouraging preclinical data on the investigational mTOR inhibitor, deforolimus, alone or in combination with the anti-androgen agent, bicalutamide, in models of prostate cancer. This investigational study shows that the combination inhibits the growth of prostate cancer cell lines in various model systems. This data provide the scientific rationale for an ongoing Phase II clinical trial examining the same combination in patients with advanced prostate...

2008-10-24 09:00:07

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today presented, for the first time, results of studies on its investigational, multi-targeted kinase inhibitor - AP24534 - showing anti-tumor activity in preclinical cancer models. These data were released at the EORTC-NCI-AACR (ENA) symposium on "Molecular Targets and Cancer Therapeutics" held in Geneva, Switzerland this week. AP24534 demonstrated potent inhibition of selected kinase targets that control tumor growth and angiogenesis, notably...

2008-10-23 09:00:10

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today presented preclinical data on the investigational mTOR inhibitor, deforolimus, alone or in combination with the anti-androgen agent, bicalutamide, in models of prostate cancer. This investigational study shows that the combination inhibits the growth of prostate cancer cell lines in various model systems. The data were presented at the EORTC-NCI-AACR (ENA) symposium on "Molecular Targets and Cancer Therapeutics" held in Geneva, Switzerland this...

2008-10-21 12:00:08

Ariad Pharmaceuticals, a developer of medicines to treat cancer, has announced the initiation of a Phase II clinical trial by Merck & Co to evaluate the safety and efficacy of oral deforolimus, Ariad's investigational mTOR inhibitor, in patients with advanced prostate cancer. In collaboration with Merck, deforolimus is currently being studied in multiple clinical trials, both alone and in combination with other therapies, in patients with several different types of cancer. Under the...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related